Invisible burden of COVID-19: enzyme replacement therapy disruptions

Creative Commons License

Kahraman A. B., Yıldız Y., Çıkı K., Akar H. T., Erdal İ., Dursun A., ...Daha Fazla

JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, cilt.34, sa.5, ss.539-545, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 34 Sayı: 5
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1515/jpem-2021-0067
  • Dergi Adı: JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CAB Abstracts, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.539-545
  • Anahtar Kelimeler: COVID-19, disruptions, enzyme replacement therapy, lysosomal storage diseases, survey, FABRY DISEASE, PATIENT
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Objectives: Lysosomal storage diseases (LSD) constitute an important group of metabolic diseases, consisting of approximately 60 disorders. In some types of lysosomal diseases, enzyme replacement therapy (ERT) is administered intravenously in weekly or biweekly doses. Unfortunately, scheduled ERT during COVID-19 was disrupted. We considered the possibility of adverse outcomes caused by the disruption in the treatment of patients with lysosomal storage disorders.